Coloplast A/S
CSE:COLO B

Watchlist Manager
Coloplast A/S Logo
Coloplast A/S
CSE:COLO B
Watchlist
Price: 891.6 DKK 2.11% Market Closed
Market Cap: 200.6B DKK
Have any thoughts about
Coloplast A/S?
Write Note

Operating Margin
Coloplast A/S

27%
Current
30%
Average
4.2%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
27%
=
Operating Profit
7.3B
/
Revenue
27B

Operating Margin Across Competitors

Country DK
Market Cap 200.9B DKK
Operating Margin
27%
Country JP
Market Cap 6.8T JPY
Operating Margin
28%
Country CH
Market Cap 37.9B CHF
Operating Margin
13%
Country US
Market Cap 16.9B USD
Operating Margin
17%
Country KR
Market Cap 9.9T KRW
Operating Margin
-245%
Country CA
Market Cap 6.9B USD
Operating Margin
4%
Country CN
Market Cap 48.6B CNY
Operating Margin
46%
Country US
Market Cap 6.3B USD
Operating Margin
32%
Country US
Market Cap 6.1B USD
Operating Margin
12%
Country UK
Market Cap 4.8B GBP
Operating Margin
13%
Country CH
Market Cap 4.9B CHF
Operating Margin
14%
No Stocks Found

Coloplast A/S
Glance View

Market Cap
200.9B DKK
Industry
Health Care

Coloplast A/S is a leading global healthcare company headquartered in Denmark, dedicated to the development of innovative medical devices and solutions for individuals with intimate healthcare needs. Founded in 1954, the company has a strong heritage built on empathy and understanding of patient challenges, which drives its continuous commitment to enhancing the quality of life for people with chronic conditions. Coloplast operates in three primary business areas: ostomy care, urology, and continence care, crafting products that empower individuals to manage their health effectively. With a presence in over 40 countries and products sold in more than 100 markets, Coloplast not only boasts a robust portfolio but also demonstrates significant global reach, setting itself apart in a competitive healthcare landscape. For investors, Coloplast presents an attractive opportunity characterized by its steady revenue growth and focus on innovation. The company has implemented a patient-centric approach, which not only fosters brand loyalty but also supports resilience in market fluctuations. With a solid track record of investing in research and development, Coloplast continually enhances its product offerings, ensuring that it remains a trusted partner for patients and healthcare providers alike. As societal trends shift towards personalized and home-based care, Coloplast's strategic initiatives aim to capitalize on these changes, making it well-positioned for sustainable growth in the long term. This strong foundation, marked by operational excellence and a commitment to corporate social responsibility, underscores Coloplast's potential to deliver both solid financial returns and positive societal impact.

COLO B Intrinsic Value
877.42 DKK
Overvaluation 2%
Intrinsic Value
Price

See Also

Discover More
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
27%
=
Operating Profit
7.3B
/
Revenue
27B
What is the Operating Margin of Coloplast A/S?

Based on Coloplast A/S's most recent financial statements, the company has Operating Margin of 27%.